08:34 AM EST, 11/07/2025 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) said Friday that Dupixent (dupilumab) for treatment of allergic fungal rhinosinusitis in adults and children aged six years and older met all primary and secondary endpoints in a phase three study.

The study showed that Dupixent "significantly" reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged six years and older compared to placebo, the companies said.

The companies further said that the US Food and Drug Administration accepted for priority review the supplemental biologics license application for Dupixent in adults and children aged six years and older with allergic fungal rhinosinusitis, with a target action date Feb. 28, 2026.